계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
Araris Biotech
About
Araris Biotech is a biotechnology platform enables the attachment of any payload to ‘off the shelf’ antibodies.
- 1 - 10
Highlights
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $24M
- Industries
- Biotechnology,Health Care
- Founded date
- Jan 1, 2019
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 4, 2022 | Series A | $24M | 1 | — | — | Detail |
